ライフサイエンスコーパス: neuroendocrine tumor

1 ding one advanced PDAC and one early grade 2 neuroendocrine tumor.

2 C) is a rare but highly aggressive cutaneous neuroendocrine tumor.

3 l examination revealed a primary gallbladder neuroendocrine tumor.

4 had a hepatic metastasis from a small-bowel neuroendocrine tumor.

5 s: gastrointestinal polyposis and pancreatic neuroendocrine tumor.

6 agon-expressing microadenomas (3 of 8) and a neuroendocrine tumor.

7 phaga species in a patient with a metastatic neuroendocrine tumor.

8 on-induced hypercalcemia due to a pancreatic neuroendocrine tumor.

9 othesis of a calcitriol producing pancreatic neuroendocrine tumor.

10 othesis of a calcitriol-producing pancreatic neuroendocrine tumor.

11 are overexpressed in neuroblastoma and other neuroendocrine tumors.

12 nesis and treatment of poorly differentiated neuroendocrine tumors.

13 s an important role in staging and restaging neuroendocrine tumors.

14 tide LAR among patients with advanced midgut neuroendocrine tumors.

15 and peptide receptor radionuclide therapy of neuroendocrine tumors.

16 ependent prognostic biomarkers of pancreatic neuroendocrine tumors.

17 ssive, somatostatin-receptor-positive midgut neuroendocrine tumors.

18 ors may be useful as a potential therapy for neuroendocrine tumors.

19 g is a widely accepted method for imaging of neuroendocrine tumors.

20 uspected pulmonary or gastroenteropancreatic neuroendocrine tumors.

21 d in the clinic for imaging and treatment of neuroendocrine tumors.

22 in 728 patients with confirmed or suspected neuroendocrine tumors.

23 ging of pulmonary and gastroenteropancreatic neuroendocrine tumors.

24 dder are very rare, representing 0.2% of all neuroendocrine tumors.

25 increasingly used for managing patients with neuroendocrine tumors.

26 for the treatment of neuroblastoma and other neuroendocrine tumors.

27 tide receptor radionuclide therapy (PRRT) of neuroendocrine tumors.

28 tivation of beta-catenin was observed in the neuroendocrine tumors.

29 on the intended management of patients with neuroendocrine tumors.

30 the impact of DOTATATE on the management of neuroendocrine tumors.

31 is a treatment for inoperable or metastatic neuroendocrine tumors.

32 d improve the availability of PET imaging of neuroendocrine tumors.

33 derivatives for the detection and staging of neuroendocrine tumors.

34 led receptor (GPCR) that is overexpressed in neuroendocrine tumors.

35 in receptors (SSTRs) in patients affected by neuroendocrine tumors.

36 radiopharmaceutical used for the therapy of neuroendocrine tumors.

37 re performed in 203 patients with metastatic neuroendocrine tumors.

38 atment of somatostatin receptor 2-expressing neuroendocrine tumors.

39 targets may be adverse prognostic factors in neuroendocrine tumors.

40 PRRT with (177)Lu-octreotate for metastatic neuroendocrine tumors.

41 plasia with the potential for evolution into neuroendocrine tumors.

42 tions in patients with liver metastases from neuroendocrine tumors.

43 node metastases in patients with pancreatic neuroendocrine tumors.

44 ((18)F-FDOPA) PET, a new diagnostic tool for neuroendocrine tumors.

45 eatment for somatostatin receptor-expressing neuroendocrine tumors.

46 ients with metastatic gastroenteropancreatic neuroendocrine tumors.

47 reatment for advanced gastroenteropancreatic neuroendocrine tumors.

48 tment for somatostatin receptor 2-expressing neuroendocrine tumors.

49 (LC) are rare and slow growing primary lung neuroendocrine tumors.

50 ty of (177)Lu-DOTATATE in humans affected by neuroendocrine tumors.

51 177)Lu-octreotate treatment of patients with neuroendocrine tumors.

52 ospective dosimetry tool in 10 patients with neuroendocrine tumors.

53 tion of SQCC) shared molecular features with neuroendocrine tumors.

54 as are infrequent, genetically heterogeneous neuroendocrine tumors.

55 view of 31 patients with advanced metastatic neuroendocrine tumors (20 with carcinoid tumors and 11 w

56 l pancreatectomies were performed mainly for neuroendocrine tumors (35%), intraductal papillary mucin

57 N) resection after appendectomy for appendix neuroendocrine tumor (A-NET) remain controversial, espec

58 eptide into the clinical setting to diagnose neuroendocrine tumors about 25 y ago, many advances have

59 u-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radion

60 mes of primary tumor resection in metastatic neuroendocrine tumors across all primary tumor sites.

61 From a prospective database of pancreatic neuroendocrine tumors, all patients with liver metastati

62 f (67)Cu-CuSarTATE in a preclinical model of neuroendocrine tumors and compare it with the standard P

63 n the biochemical diagnosis and follow-up of neuroendocrine tumors and inborn errors of metabolism.

64 The UPR is upregulated in pancreatic neuroendocrine tumors and its inhibition significantly r

65 or organs at risk (OARs) in the treatment of neuroendocrine tumors and meningioma.

66 e summarizes recent advances in the field of neuroendocrine tumors and places them into context for b

67 afe treatment for patients with metastasized neuroendocrine tumors and prostate cancer, and the occur

68 or different radiopharmaceuticals applied to neuroendocrine tumors and prostate cancer.

69 port the use of certain radiolabeled AAs for neuroendocrine tumors and prostate cancer.

70 ed our patient database for TLS after RLT in neuroendocrine tumors and prostate cancer.

71 and peptide receptor radionuclide therapy of neuroendocrine tumors and provide successful imaging and

72 pancreatic ductal adenocarcinoma as well as neuroendocrine tumors and rarer subtypes of cancers of t

73 on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer.

74 iately differentiated to well-differentiated neuroendocrine tumors and who underwent (68)Ga-DOTATATE

75 al adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all died within 65 weeks.

76 , these results have been obtained mostly in neuroendocrine tumors, and only limited data are availab

77 ide therapy in the therapeutic algorithm for neuroendocrine tumors; and establish the basis for appro

78 Neuroendocrine tumors are a group of biologically and cl

79 hough up to 30-40% of gastroenteropancreatic neuroendocrine tumors are known to be functional (i.e. p

80 Prognostic biomarkers for the pancreatic neuroendocrine tumors are needed.

81 Gastroenteropancreatic neuroendocrine tumors are relatively rare neoplasms, cha

82 e secreted), calcitriol secreting pancreatic neuroendocrine tumors are very rare.

83 of the gastrointestinal tract and low grade neuroendocrine tumor as part of the TSC syndromic phenot

84 c radionuclide approach to the management of neuroendocrine tumors, as described by the inventor of t

85 are serotonin-secreting well-differentiated neuroendocrine tumors believed to originate from enteroc

86 l papillary mucinous neoplasm and pancreatic neuroendocrine tumor biology affect patient outcomes and

87 ound on many human cancers, most classically neuroendocrine tumors but also others.

88 , WaGa and Mkl-1 cells were similar to other neuroendocrine tumors, but the variant cell lines were n

89 nomenclatures have been proposed to stratify neuroendocrine tumors, but the World Health Organization

90 nce from sequencing indicates that, although neuroendocrine tumors can arise de novo, they can also d

91 Gastrinomas are rare functional neuroendocrine tumors causing the Zollinger-Ellison synd

92 lation experiments with the human pancreatic neuroendocrine tumor cell line BON-1 were performed at b

93 iodobenzylguanidine ((131)I-MIBG) therapy of neuroendocrine tumors comprises different dosing schemes

94 Paragangliomas are benign neuroendocrine tumors derived from the glomus cells of t

95 e imaging properties in an in vivo model for neuroendocrine tumors, despite the fact that the injecte

96 treatment at an academic institution, and a neuroendocrine tumor diagnosis (all P < 0.01).

97 al biology screen and identified a subset of neuroendocrine tumors displaying a striking pattern of s

98 in the clinical evaluation and management of neuroendocrine tumors, especially in neuroblastoma, para

99 rrently a mainstay in the evaluation of many neuroendocrine tumors, especially neuroblastoma.

100 tidisciplinary consensus panel consisting of neuroendocrine tumor experts, including oncologists, gas

101 le might be advantageous for imaging because neuroendocrine tumors express different subtypes of soma

102 ses for patients with gastroenteropancreatic neuroendocrine tumors (GEP NET) after peptide receptor r

103 ignant melanoma (MM), gastroenteropancreatic neuroendocrine tumors (GEP NETs), and prostate cancer (P

104 TATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs).

105 arned a major role in gastroenteropancreatic neuroendocrine tumors (GEP NETs).

106 the characterization of gastroendopancreatic neuroendocrine tumors (GEP-NET).

107 he same patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to evaluate the cli

108 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous gro

109 eir perceived rarity, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rising in incidence

110 Gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) are increasing in incide

111 Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are indolent neoplasms p

112 ients with metastatic gastroenteropancreatic neuroendocrine tumors (GEPNETs).

113 lished prognostic factor in gastrointestinal neuroendocrine tumors (GI-NETs) and defines tumor grade.

114 vival benefit in metastatic gastrointestinal neuroendocrine tumors (GI-NETs); however, few studies ha

115 ) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival.

116 d among patients with early-stage pancreatic neuroendocrine tumors has not been well established.

117 Gastroenteropancreatic neuroendocrine tumors have occasionally been described i

118 ach (8%) and colon cancer, multiple myeloma, neuroendocrine tumor, head and neck squamous cell carcin

119 differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment i

120 ms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor

121 may be useful when stratifying patients with neuroendocrine tumors in future trials.

122 h cancer cells and macrophages in pancreatic neuroendocrine tumors in humans and mice.

123 The diagnosis of neuroendocrine tumors in particular has been a prime exa

124 egulated in lymphatics in or near pancreatic neuroendocrine tumors in RIP-Tag2 transgenic mice and wh

125 Neuroendocrine tumor incidence, prevalence, and OS rates

126 nificance of specific proteins in pancreatic neuroendocrine tumors including insulinoma.

127 etinoblastoma, a tumor of neural origin, and neuroendocrine tumors including small cell lung cancer a

128 CN is a driver mutation in a subset of human neuroendocrine tumors, including neuroblastoma.

129 iods of disease control in a wide variety of neuroendocrine tumors involving the pancreas.

130 5HTP) whose excellent in vivo performance in neuroendocrine tumors is mainly attributed to its decarb

131 te that the similarity of KS lesion cells to neuroendocrine tumors is probably a result of KSHV infec

132 tin receptor, which is overexpressed by many neuroendocrine tumors, is a well-known target for molecu

133 Serum chromogranin A, a marker for neuroendocrine tumors, is elevated in patients taking pr

134 Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the r

135 ve tumors do not express pRb and express the neuroendocrine tumor markers synaptophysin and microtubu

136 t in patients with liver-dominant metastatic neuroendocrine tumors (mNETs), despite the absence of le

137 h- and low-specific-activity (18)F-DOPA in a neuroendocrine tumor model to determine whether this dif

138 sin B (CtsB) and CtsS in a murine pancreatic neuroendocrine tumor model.

139 in a preclinical in vivo model of endogenous neuroendocrine tumors (multiple endocrine neoplasia [MEN

140 nancies (colorectal cancer [n = 195, 38.8%], neuroendocrine tumors [n = 77, 15.3%], breast cancer [n

141 oversy remains over whether small pancreatic neuroendocrine tumors need to be surgically resected or

142 ovel multi-gene liquid biopsy has utility in neuroendocrine tumor (NET) diagnosis and identification

143 e kinase; MTOR) pathway in the regulation of neuroendocrine tumor (NET) growth.

144 tide receptor radionuclide therapy (PRRT) in neuroendocrine tumor (NET) patients treated with (90)Y-D

145 tide receptor radionuclide therapy (PRRT) in neuroendocrine tumor (NET) patients treated with (90)Y-D

146 is widely used for guiding the management of neuroendocrine tumor (NET) patients.

147 Mechanisms of neuroendocrine tumor (NET) proliferation are poorly unde

148 rgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases.

149 TATE PET/CT interpretations in patients with neuroendocrine tumor (NET).

150 s, and emerging anatomic modalities to stage neuroendocrine tumor (NET).

151 gnosis, follow-up, and treatment planning of neuroendocrine tumor (NET).

152 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the

153 The incidence of neuroendocrine tumors (NET) has increased dramatically i

154 antation (LT) for liver metastases (LM) from neuroendocrine tumors (NET) over a 27-year period.

155 The application of this beta- RGS to neuroendocrine tumors (NET) requires study of the uptake

156 iliary malignancies including non-viral HCC, neuroendocrine tumors (NET), and colorectal carcinoma wi

157 are highly expressed in well-differentiated neuroendocrine tumors (NET).

158 had colorectal cancer (CRC; n = 195, 38.8%), neuroendocrine tumors (NET; n = 77, 15.3%), mammary canc

159 In neuroendocrine tumors, NET can be targeted for imaging a

160 IMS: Survival times vary among patients with neuroendocrine tumors (NETs) - even among those with the

161 Patients with neuroendocrine tumors (NETs) are often treated with soma

162 Pancreatic neuroendocrine tumors (NETs) are rare neoplasms for whic

163 The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, b

164 Neuroendocrine tumors (NETs) are uncommon tumors with in

165 Neuroendocrine tumors (NETs) can be treated by peptide r

166 Neuroendocrine tumors (NETs) can be visualized using rad

167 Neuroendocrine tumors (NETs) comprise a heterogeneous gr

168 de receptor radionuclide therapy in advanced neuroendocrine tumors (NETs) demonstrates a limited obje

169 ECT have been used for functional imaging of neuroendocrine tumors (NETs) for the last 2 decades.

170 Small intestinal (SI) neuroendocrine tumors (NETs) have heterogeneous outcomes

171 s with inoperable or unresectable pancreatic neuroendocrine tumors (NETs) have limited treatment opti

172 on in management of patients with metastatic neuroendocrine tumors (NETs) is controversial.

173 retin receptor family, overexpressed on many neuroendocrine tumors (NETs) is of great importance beca

174 ne ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and f

175 A high proportion of gut and bronchial neuroendocrine tumors (NETs) overexpresses somatostatin

176 Purpose Treatment options for neuroendocrine tumors (NETs) remain limited.

177 sst2) antagonists are better tools to target neuroendocrine tumors (NETs) than sst2 agonists.

178 ate ((18)F-FET-betaAG-TOCA) in patients with neuroendocrine tumors (NETs) to evaluate biodistribution

179 ; range, 20-90 y) with histologically proven neuroendocrine tumors (NETs) underwent both (68)Ga-DOTAT

180 udy, 176 patients with measurable metastatic neuroendocrine tumors (NETs) were recruited.

181 The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled somatosta

182 iagnosis of somatostatin receptor-expressing neuroendocrine tumors (NETs), and SUV measurements are s

183 l to the diagnosis of gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, espec

184 In the treatment of neuroendocrine tumors (NETs), complete surgical removal

185 atients with suspected but yet not localized neuroendocrine tumors (NETs), early diagnosis or reliabl

186 related to nodal involvement in appendiceal neuroendocrine tumors (NETs), to identify patients who s

187 to development and maintenance of pancreatic neuroendocrine tumors (NETs), with special reference to

188 y in Europe over the past decade for imaging neuroendocrine tumors (NETs).

189 to characterize gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).

190 Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs).

191 macokinetics, and dosimetry of (18)F-MFBG in neuroendocrine tumors (NETs).

192 )In-DOTATATE) of patients with meningioma or neuroendocrine tumors (NETs).

193 s with somatostatin receptor (SSTR)-positive neuroendocrine tumors (NETs).

194 sion-free survival in patients with advanced neuroendocrine tumors (NETs).

195 tment of gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).

196 ng classification for jejunal-ileal (midgut) neuroendocrine tumors (NETs).

197 sted for therapy monitoring in patients with neuroendocrine tumors (NETs).

198 sembles other types of poorly differentiated neuroendocrine tumors (NETs).

199 ts perform better than agonists in detecting neuroendocrine tumors (NETs).

200 use mortality after radiopeptide therapy for neuroendocrine tumors (NETs).

201 essed from planar images in 29 patients with neuroendocrine tumors (NETs; n = 21) or meningioma (n =

202 nically approved agents for the treatment of neuroendocrine tumors, neuroblastoma, and non-Hodgkin ly

203 he pathogenesis of gastrinoma and pancreatic neuroendocrine tumors, new prognostic classification sys

204 Nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs) are often indolent ne

205 Patients with nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) have poorer survival th

206 ated antigen otherwise found in melanoma and neuroendocrine tumors; normal expression is largely rest

207 horylated at Ser341/343 in receptor-positive neuroendocrine tumors obtained from 10 octreotide-treate

208 l carcinoma was first described in 1972 as a neuroendocrine tumor of skin, most cases of which were r

209 MCC is a rare, clinically aggressive neuroendocrine tumor of the skin with a high propensity

210 the urinary bladder is a rare and aggressive neuroendocrine tumor of the urinary bladder.

211 nfunctioning, somatostatin receptor-positive neuroendocrine tumors of grade 1 or 2 (a tumor prolifera

212 ng patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%).

213 The primary neuroendocrine tumors of the gallbladder are very rare,

214 y neoplasms, cystic variations of pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinomas

215 Derived from endocrine cells, pancreatic neuroendocrine tumors (PanNET) universally hypersecrete

216 modulated by PDGF-DD signaling in pancreatic neuroendocrine tumors (PanNET).

217 al adenocarcinoma (PDAC, n = 58), pancreatic neuroendocrine tumors (PanNET, n = 42), intraductal papi

218 , its specific functions in human pancreatic neuroendocrine tumors (PanNETs) and spontaneous mouse mo

219 Pancreatic neuroendocrine tumors (PanNETs) are a relatively rare bu

220 Pancreatic neuroendocrine tumors (PanNETs) are a type of pancreatic

221 ular alterations in small primary pancreatic neuroendocrine tumors (PanNETs) associated with the deve

222 esis and malignant progression of pancreatic neuroendocrine tumors (PanNETs) in a genetically enginee

223 Efforts to model human pancreatic neuroendocrine tumors (PanNETs) in animals have been mod

224 of localized well-differentiated pancreatic neuroendocrine tumors (panNETs) is controversial and pri

225 e utilized after resection of all pancreatic neuroendocrine tumors (PanNETs).

226 potential therapeutic target in a subset of neuroendocrine tumors, particularly small cell lung canc

227 Methods: PRRT-naive adult neuroendocrine tumor patients with liver-dominant metast

228 en the high frequency of liver metastases in neuroendocrine tumor patients, we aimed to determine whe

229 ed on tumor cells is successfully applied in neuroendocrine tumor patients.

230 Serum markers include chromogranin A for neuroendocrine tumors, pepsinogen I for gastric atrophy,

231 The incidence of pancreatic neuroendocrine tumor (PNET) is increasing, and it presen

232 -hydroxycholesterol (24S-HC) in a pancreatic neuroendocrine tumor (pNET) model commonly used to study

233 rognostic factor in patients with pancreatic neuroendocrine tumor (pNET).

234 Pancreatic neuroendocrine tumors (pNETs) are a rare and heterogeneo

235 Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically h

236 Management of pancreatic neuroendocrine tumors (PNETs) associated with von Hippel

237 Most pancreatic neuroendocrine tumors (PNETs) do not produce excess horm

238 Pancreatic neuroendocrine tumors (PNETs) may evolve and cause hormo

239 is significantly downregulated in pancreatic neuroendocrine tumors (PNETs).

240 e are few effective therapies for pancreatic neuroendocrine tumors (PNETs).

241 T/mTOR signaling is a hallmark of pancreatic neuroendocrine tumors (PNETs).

242 ning parameters for patients with pancreatic neuroendocrine tumors (PNETs; 124 patients and 381 scans

243 d DOTATATE peptides, which are used to image neuroendocrine tumors, predict treatment response, and t

244 colorectal cancer (r = 0.2; P < 0.001), and neuroendocrine tumors (r = 0.2; P < 0.01).

245 prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according

246 The diagnosis of neuroendocrine tumor relies on clinical manifestation, l

247 similarity of KS lesion endothelial cells to neuroendocrine tumors remains unknown.

248 ncy due to a calcitriol-producing pancreatic neuroendocrine tumor, responding to peptide receptor rad

249 highly angiogenic mouse model of pancreatic neuroendocrine tumor RIP-Tag2.

250 emic circulation from metastatic small bowel neuroendocrine tumors (SB NET) causes CS.

251 Though a rare entity, primary neuroendocrine tumor should be considered in the differe

252 tment of well differentiated small intestine neuroendocrine tumors (SI-NET).

253 Small intestinal neuroendocrine tumors (SI-NETs) are serotonin-secreting

254 Small intestine neuroendocrine tumors (SI-NETs) are the most common mali

255 Patients with small intestinal neuroendocrine tumors (SI-NETs) frequently develop sprea

256 The diagnosed incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, and the u

257 ng way in our understanding and treatment of neuroendocrine tumors since the term "karzinoide" was co

258 oint Committee on Cancer (AJCC) and European Neuroendocrine Tumor Society (ENETS) are prognostic for

259 According to the European NeuroEndocrine Tumor Society (ENETS) recommendations, 85

260 Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear

261 Methods: Using PRRT databases at 2 European Neuroendocrine Tumor Society Centers of Excellence, case

262 ion was 0.85, which was higher than European Neuroendocrine Tumors Society/American Joint Committee o

263 of benefit in the ongoing RAD001 In Advanced Neuroendocrine Tumors study (RADIANT-4).

264 MEN1 mutations frequently cause neuroendocrine tumors such as gastrinomas, characterized

265 heranostics; review its current role in some neuroendocrine tumors, such as neuroblastoma, paragangli

266 umor diameter-based algorithm for pancreatic neuroendocrine tumor surveillance may potentially reduce

267 in RIP-Tag2 transgenic mice with pancreatic neuroendocrine tumors that developed spontaneously and p

268 e most common type of functioning pancreatic neuroendocrine tumors that occur sporadically or as a pa

269 o had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate

270 Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single dise

271 ter cremation of a patient with a pancreatic neuroendocrine tumor treated with the radioisotope 2 day

272 ds: Data were available for 10 patients with neuroendocrine tumors treated with (177)Lu-DOTATATE and

273 his study included 46 patients with advanced neuroendocrine tumors treated with at least 2 fractions

274 he dose-response relationship for pancreatic neuroendocrine tumors treated with PRRT using (177)Lu-DO

275 in 24 patients with metastasized pancreatic neuroendocrine tumors treated with repeated cycles of (1

276 a treated with (131)I-tositumomab; case 2, a neuroendocrine tumor treatment simulated with (177)Lu-pe

277 Sixty consecutive patients with neuroendocrine tumors underwent both (68)Ga-DOTATOC and

278 Ten patients with metastatic neuroendocrine tumors underwent one 45-min dynamic and 3

279 raphy, we demonstrated that-for instance, in neuroendocrine tumors-up to 3 receptors can be coexpress

280 curing early-stage disease while preventing neuroendocrine tumors using c-Kit-targeted therapy.

281 therapy of somatostatin receptor-expressing neuroendocrine tumors using somatostatin receptor radiol

282 cessive overproduction of calcitriol by this neuroendocrine tumor was the cause of the refractory hyp

283 of UCH-L1 and alpha-internexin in pancreatic neuroendocrine tumors was significantly associated with

284 l reported 2 female patients with pancreatic neuroendocrine tumors, WDS, and achlorhydria.

285 In 4 consecutive patients with advanced neuroendocrine tumors, we evaluated whether treatment wi

286 ty and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PE

287 Ten patients diagnosed with neuroendocrine tumors were included.

288 Patients with advanced midgut neuroendocrine tumors who have had disease progression d

289 consecutive patients with known or suspected neuroendocrine tumors, who were evaluated with DOTATATE.

290 Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early dissemination and dismal

291 l carcinoma (MCC) is an aggressive cutaneous neuroendocrine tumor with high mortality rates.

292 trasound guided biopsy revealed a pancreatic neuroendocrine tumor with multifocal liver metastases, s

293 Treatment of neuroendocrine tumors with (177)Lu-octreotate results in

294 Two hundred patients with metastatic neuroendocrine tumors with high somatostatin receptor ex

295 omatostatin analogs for in vivo diagnosis of neuroendocrine tumors with PET.

296 Treatment of neuroendocrine tumors with radiolabeled sst antagonists

297 t 27, 29, and 34 months) and 4 node-positive neuroendocrine tumors (with 1 hepatic recurrence at 66 m

298 analogs is a well-established treatment for neuroendocrine tumors, with (177)Lu-DOTATATE having acqu

299 ave shown promising results in patients with neuroendocrine tumors, with a higher lesion detection ra

300 medical management of gastroenteropancreatic neuroendocrine tumors within the context of the larger m